Crowley John J 4

What Happened John J. Crowley, Chief Financial Officer of Centessa Pharmaceuticals plc (CNTA), was granted a total of 226,000 equity awards on February 2, 2026 — 45,000 reported as ordinary-share awards and 181,000 reported as derivative awards (RSUs). The awards were granted at $0.00 per share (no cash paid). These RSUs represent the contingent right to receive ordinary shares (which may be represented by American Depositary Shares).

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 3, 2026 (timely filing).
• Grants: 45,000 shares @ $0.00; 181,000 derivative shares (RSUs) @ $0.00; total = 226,000 RSUs; reported value $0.
• Vesting: Footnote states the RSUs vest and will be settled in four equal annual installments, with the first annual vesting on February 2, 2027.
• ADS note: Ordinary shares may be represented by ADSs, each currently representing one ordinary share (footnote).
• Additional footnote: filing also includes a note that "1/48th of the shares subject to such option shall vest in equal monthly installments" with the first installment on March 2, 2026 — this appears to reference a different/related vesting schedule included in the filing.
• Shares owned after the transaction: not specified in the provided excerpt.
• Filing timeliness: filed within one business day of the transaction (no late-filing indication).

Context

• These were grants of Restricted Share Units (RSUs), not open-market purchases or sales. RSU grants are compensation and do not indicate an immediate cash investment by the insider; they convert to actual shares only as they vest.
• Because the awards were granted at $0.00, there was no cash exchanged; the economic value will depend on Centessa’s share price when each tranche vests/settles.